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Abstract
Objectives: Evaluated the effects of atomoxetine on the reading abilities of children with dyslexia only or attention-deficit/
hyperactivity disorder (ADHD) and comorbid dyslexia.
Methods: Children aged 10–16 years (N= 209) met Diagnostic and Statistical Manual of Mental Disorders, 4th Edition,
Text Revision (DSM-IV-TR) criteria for dyslexia only (n = 58), ADHD and comorbid dyslexia (n = 124), or ADHD only
(n = 27) and were of normal intelligence. Patients were treated with atomoxetine (1.0–1.4mg/kg/day) or placebo in a
16-week, randomized, placebo-controlled, double-blind trial. The dyslexia-only and ADHD and comorbid dyslexia groups
were randomized 1:1; the ADHD-only group received atomoxetine in a blinded manner. Reading abilities were measured
with the Woodcock Johnson III (WJIII), Comprehensive Test of Phonological Processing (CTOPP), Gray Oral Reading
Tests-4, and Test of Word Reading Efficiency.
Results: Atomoxetine-treated dyslexia-only patients compared with placebo patients had significantly greater improvement
( p < 0.02) with moderate to approaching high effect sizes (ES) on WJIII Word Attack (ES = 0.72), Basic Reading Skills
(ES = 0.48), and Reading Vocabulary (ES = 0.73). In the atomoxetine-treated ADHD and comorbid dyslexia group, im-
provement on the CTOPP Elision measure (ES = 0.50) was significantly greater compared with placebo ( p < 0.02). Total,
inattentive, and hyperactive/impulsive ADHD symptom reductions were significant in the atomoxetine-treated ADHD and
comorbid dyslexia group compared with placebo, and from baseline in the ADHD-only group ( p £ 0.02). ADHD symptom
improvements in the ADHD and comorbid dyslexia group were not correlated with improvements in reading.
Conclusions: Atomoxetine treatment improved reading scores in patients with dyslexia only and ADHD and comorbid
dyslexia. Improvements for patients with dyslexia only were in critical components of reading, including decoding and reading
vocabulary. For patients with ADHD and comorbid dyslexia, improvements in reading scores were distinct from improvement
in ADHD inattention symptoms alone. These data represent the first report of improvements in reading measures following
pharmacotherapy treatment in patients with dyslexia only evaluated in a randomized, double-blind trial.
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Introduction
Dyslexia (or specific reading disability) represents anunexpected difficulty in reading for an individual’s age, in-
telligence, or professional status. Fluent reading—reading that is
rapid, automatic, and with good intonation (prosody)—is very
frequently affected, even in dyslexic readers who have learned to
read accurately (Shaywitz 1998; Lyon et al. 2003; Ferrer et al.
2010). Dyslexia is highly prevalent and persistent and occurs
worldwide. In the United States, dyslexia rates range from 5% to
17.5% (Felton et al. 1990; Bruck 1992; Francis et al. 1996;
Shaywitz et al. 1999; Shaywitz 2003). Worldwide prevalence
rates also are high, with rates ranging from 8% in mainland
China to almost 13% in Hong Kong (Chan et al. 2007; Liu et al.
2012).
At its core, dyslexia is primarily a problem with phonological
processing (i.e., getting to the elemental sounds of spoken lan-
guage) affecting both spoken and written language. To learn to
read, the child has to develop the unconscious awareness that
spoken words can be pulled apart into the elemental particles of
speech (i.e., phonemes) and that the letters in a written word
represent these sounds. Evidence from a number of lines of in-
vestigation provides overwhelming evidence that a deficit in pho-
nology represents the most robust and specific correlate of dyslexia
(Liberman and Shankweiler 1991; Morris et al. 1998; Shaywitz
1998, 2003).
In addition to the centrality of phonological mechanisms in
dyslexia, recent evidence supports an important role for attentional
mechanisms in dyslexia (Shaywitz and Shaywitz 2008; Kovelman
et al. 2012). Cognitive studies suggest that attention is a critical,
overlooked component facilitating the translation of print into
speech and is particularly important for achieving fluent reading
(Reynolds and Besner 2006). Further evidence that attentional
processes may be important in reading comes from studies em-
phasizing the comorbidity of dyslexia and attention-deficit/hyperactivity
disorder (ADHD) (August and Garfinkel 1990; Dykman and
Ackerman 1991; Shaywitz et al. 1994; Willcutt and Pennington
2000; Germano et al. 2010; Yoshimasu et al. 2010). Estimates of
rates in those with dyslexia and comorbid ADHD range from 9%
to as high as 60%, whereas patients initially diagnosed with
ADHD have a co-occurrence of dyslexia reported to range
from 15% to 45% (Willcutt and Pennington 2000; Willcutt et al.
2001; Carroll et al. 2005; Maughan and Carroll 2006; Sexton
et al. 2012).
The role of attentional mechanisms in dyslexia is further
supported by a recent functional magnetic resonance imaging con-
nectivity analysis. Using data-driven brain parcellation, connectivity
profiles were compared between dyslexic and typical readers. Re-
lative to typical readers, those with dyslexia demonstrated decreased
connectivity between posterior reading systems and prefrontal at-
tentional regions (Finn et al. 2014).
The consequences of dyslexia have profound long-term im-
pacts on the educational, employment, and health outcomes of
children with dyslexia, all of which are significantly worse than
for their typical reading peers. Thus, high school dropout rates for
students classified as learning disabled (80%–90% of whom are
dyslexic) are three to four times as high as for typical readers
(Blackorby and Wagner 1996). Furthermore, men and women
with lower levels of literacy are more likely to be at or near
national poverty levels. They tend to rely on public assistance to
support themselves in contrast to those with higher levels of lit-
eracy who are significantly more likely to be employed and to
avoid unemployment; to be active labor force participants; to be
employed in professional, management-related, and technical
(rather than service, craft, laborer/helper) occupations; to have
supervisory responsibilities on their job; and to earn significantly
more (two to three times more) weekly and annually (Kirsch et al.
1993; Reder and Vogel 1997; Rudd et al. 2004, 2007; Sum et al.
2004; Kutner et al. 2007; Tamassia et al. 2007; Bynner and Par-
sons 2009; Kruidenier et al. 2010). In addition, adults with low
levels of literacy have difficulty accessing or understanding
health-related information, are hospitalized more often, and do
not manage chronic diseases as well (Rudd et al. 2004, 2007;
Kutner et al. 2006). Overall, they are more likely to experience
poor health and a shortened life span (Baker et al. 1997; Rudd
et al. 2000; Kutner et al. 2006; Marcus 2006). A more recent study
showed that the odds of dying among low-educated (no high
school diploma) white women were significantly greater than
among peers with a high school, college, or advanced degree
(Montez and Zajacova 2013).
It has been known for over 2 decades that even with the best
reading interventions, many first- and second-grade children with
dyslexia fail to learn to read proficiently (Torgesen 2000). Most
recently, a review of interventions for dyslexia found that the best
current reading interventions have produced only limited success
and that significant numbers of children receiving these inter-
ventions remain poor readers (Compton et al. 2014). Such dis-
couraging findings mandate that other treatment modalities
be developed.
Pharmacotherapy for ADHD is now more than 75 years old,
while only recently have studies begun to examine potential
pharmacological interventions for patients with dyslexia only
and ADHD and comorbid dyslexia (ADHD+D). For example,
reports in small samples that did not include dyslexia-only pa-
tients suggest that stimulants may have beneficial effects on
reading in children with ADHD +D (Grizenko et al. 2006;
Keulers et al. 2007; Bental and Tirosh 2008; Williamson et al.
2014). Small clinical trials have also demonstrated improved
reading scores in patients with ADHD +D during treatment with
atomoxetine (de Jong et al. 2009; Sumner et al. 2009; Wietecha
et al. 2013).
The current study was designed to more comprehensively and
systematically evaluate the efficacy of atomoxetine treatment in
the dyslexia-only and ADHD +D adolescent populations by in-
clusion of a larger sample, a placebo control condition, and a
longer trial duration. In a separate article, we reported the effects
of atomoxetine on core symptoms of ADHD in pediatric patients
with ADHD +D (Wietecha et al. 2013). The focus of this report is
to evaluate the effect of atomoxetine compared to placebo on
reading abilities of pediatric patients with dyslexia only or
ADHD+D.
Methods
Patients
All patients with dyslexia only and ADHD +D met criteria for
dyslexia at the second screening visit defined as follows: at least a
22-point discrepancy between the 4-subtest version of theWechsler
Abbreviated Scale of Intelligence (WASI) Verbal Intelligence
Quotient (IQ) or Performance IQ (whichever was higher) and the
Woodcock Johnson III (WJIII) Word Attack score, Word Identi-
fication score, or Basic Reading Skills score; or a standard score
of 89 or lower (<25th percentile) on the WJIII Word Attack
score, Word Identification score, or Basic Reading Skills score
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(Weschler 1999; Woodcock et al. 2001). All patients with ADHD
only and ADHD +D met Diagnostic and Statistical Manual of
Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR)
(American Psychiatric Association 2000) diagnostic criteria for
ADHD, confirmed during the first screening visit by administering
the Kiddie Schedule for Affective Disorders and Schizophrenia for
School-Age Children-Present and Lifetime Version–Behavioral
component (Kaufman et al. 1997). In addition, patients with
ADHD +D and ADHD only were required to have an Attention-
Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version:
Investigator-Administered and Scored (ADHDRS-IV-Parent:Inv)
total score of at least 1.5 standard deviations above age and gender
norms at the second and third screening visits (Faries et al. 2001).
All patients had a standard score of at least 80 on the Full Scale IQ
of the WASI at the first screening visit. Patients were 10 to 16
years old at the time of consent. Patients were excluded from the
study if they had a documented history of bipolar I or bipolar II
disorder, psychosis, autism, Asperger’s syndrome, or pervasive
developmental disorder, or were currently taking anticonvulsants
for seizure control.
Parents or caretakers provided written consent for their chil-
dren to participate in the study, and children also provided as-
sent. The study protocol was approved by each site’s ethics
review board. This study was conducted in accordance with the
ethical principles that have their origin in the Declaration of
Helsinki and are consistent with good clinical practices and
applicable laws and regulations.
Study design
The study was a multicenter outpatient, randomized, placebo-
controlled, 16-week, double-blind, Phase 4 study of atomoxetine
(0.5mg/[kg$day] for 3 days, then 1.0–1.4mg/[kg$day]) once
daily in children and adolescents with dyslexia only, ADHD+D,
or ADHD only conducted in the United States between 2008 and
2011. The detailed description of the study design and primary
efficacy ADHD outcomes for this study has been reported in
an earlier publication (Wietecha et al. 2013). Briefly, after an
*2-week-long screening phase, dyslexia-only and ADHD +D
patients were randomized 1:1 to atomoxetine or placebo treat-
ment for 16 weeks (acute treatment phase). All ADHD-only pa-
tients received atomoxetine for the 16-week acute phase. However,
to mitigate potential treatment bias effects in the ADHD-only
group, patients and site personnel were informed that assignment to
placebo treatment was possible during the initial 16-week acute
phase. After completing the acute treatment phase, patients were
eligible to enter a 16-week, open-label extension phase in which all
patients received atomoxetine. Only the reading outcome results
from the 16-week, double-blind, placebo-controlled acute phase
are presented.
Efficacy measures
The academic measures used in this study are validated and have
well-documented test–retest reliability (Torgesen et al. 1999;
Wagner et al. 1999; Wiederholt and Bryant 2001; Woodcock et al.
2001). Changes in reading skills were measured by the WJIII
reading subtests and composite, the Comprehensive Test of Pho-
nological Processing (CTOPP), the Gray Oral Reading Tests-4
(GORT-4), and the Test of Word Reading Efficiency (TOWRE)
(Torgesen et al. 1999; Wagner et al. 1999; Wiederholt and Bryant
2001; Woodcock et al. 2001). Parallel forms for the WJIII, GORT-
4, and TOWRE were alternated across targeted visits. The WJIII
tasks included Word Identification, a measure of real word identi-
fication;Word Attack, a measure of pseudoword decoding; Spelling;
Passage Comprehension; and Reading Vocabulary. Composite
measures derived from these subtests include Basic Reading
Skills, a combination of Word Identification and Word Attack, and
Reading Comprehension, a combination of Passage Comprehen-
sion and Reading Vocabulary (Woodcock et al. 2001). The CTOPP
assesses phonological awareness, phonological memory, and rapid
naming (Wagner et al. 1999). The GORT-4 measures oral reading
rate, accuracy, fluency, and comprehension (Wiederholt and Bry-
ant 2001). The TOWRE is a measure of an individual’s ability to
pronounce printed words and nonwords accurately and fluently and
contains two subtests: Sight Word Efficiency and Phonemic De-
coding Efficiency. The TOWRE provides an assessment of speed
and accuracy of visually based, context-free word reading skills
(Torgesen et al. 1999).
Changes in ADHD symptoms from baseline to week 16 were
assessed in all diagnostic groups using the ADHDRS-IV-Parent:Inv
total and subscale scores.
Statistical analyses
All analyses of reading ability scores were done on an intent-
to-treat basis. Reading ability data were analyzed with last-
observation-carried-forward analyses using fixed-effects analysis
of covariance (ANCOVA) models with terms for treatment group,
study site, gender, and age. Type III sums of squares were used for
between-treatment tests. Changes within treatment were assessed
using Student’s t-test applied to the least-squares mean (LSM) for
the group from the ANCOVA model. All tests of treatment effects
were conducted at a two-sided alpha level of 0.05. Effect sizes (ES)
were calculated by dividing the treatment group differences in the
LSM changes by the pooled standard deviation of the changes.
Secondary endpoints were not adjusted for testing of multiple hy-
potheses, with the intention of showing the actual results that could
identify areas in which more research could be warranted. Spear-
man correlation coefficients were determined between changes in
ADHDRS-IV-Parent:Inv (Total and Inattentive and Hyper-
active/Impulsive subscales), demographic baseline parameters
(age, gender, ethnicity, income status, education, ADHD sub-
type), and all reading ability measures at 16 weeks. Categories of
ethnicity were predefined by the sponsor.
The prespecified analysis for the trial was an ANCOVA model,
with terms for treatment, study site, baseline score, gender, and age,
on reading measures comparing atomoxetine and placebo in sub-
jects with dyslexia only and ADHD +D after 16 weeks. A post hoc
analysis was conducted to correct the adjustment for baseline
scores, which may not have been an appropriate analysis as all
patients did not have dyslexia and ADHD. In this post hoc analysis,
the data were examined with the term for baseline score excluded
from the model.
Results
Demographics and safety
The diagnostic sample of the 209 randomized patients who
entered the acute phase included 58 with dyslexia only (n= 29
atomoxetine; n = 29 placebo), 124 with ADHD +D (n= 64 ato-
moxetine; n= 60 placebo), and 27 with ADHD only. In the ato-
moxetine group, 7.5% of patients discontinued due to an adverse
event compared with 2.2% in the placebo group. A total of 86
patients in the atomoxetine group and 73 patients in the placebo
group completed the study (Fig. 1). More than half the patients
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were male (62%) with a mean age of 12 years (Table 1). Nearly
equal numbers of patients presented with the inattentive or com-
bined ADHD subtypes and the distribution between treatment
groups was similar. The baseline characteristics for educational
services by diagnostic group are described in Supplementary
Table S1 (Supplementary Data are available online at www
.liebertpub.com/cap).
More patients in the atomoxetine group experienced ‡1 ad-
verse event compared with placebo ( p= 0.046) (Supplementary
Table S2). The most common adverse events included nausea,
FIG. 1. Flow diagram of subject disposition by treatment and diagnostic category during 16-week, double-blind phase.
Table 1. Baseline Demographics and Characteristics
Dyslexia only ADHD+dyslexia ADHD only Total
n = 58 n= 124 n = 27 N = 209
ATX PBO ATX PBO ATX ATX PBO
n= 29 n = 29 n = 64 n = 60 n = 27 n= 120 n = 89
Age (years), mean 12.2 12.8 12.2 12.3 12.3 12.2 12.4
Range 10.0–16.8 10.1–17.0 10.1–16.1 10.1–17.0 10.0–16.4 10.0–16.8 10.1–17.0
Gender (male), n (%) 22 (75.9) 15 (51.7) 39 (60.9) 40 (66.7) 13 (48.1) 74 (61.7) 55 (61.8)
Ethnicity, n (%)
White 23 (79.3) 21 (72.4) 41 (64.1) 45 (75.0) 22 (81.5) 86 (71.7) 66 (74.2)
African American 2 (6.9) 5 (17.2) 10 (15.6) 6 (10.0) 1 (3.7) 13 (10.8) 11 (12.4)
Hispanic 4 (13.8) 3 (10.3) 11 (17.2) 8 (13.3) 3 (11.1) 18 (15.0) 11 (12.4)
East Asian 0 (0) 0 (0) 1 (1.6) 1 (1.7) 1 (3.7) 2 (1.7) 1 (1.1)
West Asian 0 (0) 0 (0) 1 (1.6) 0 (0) 0 (0) 1 (0.8) 0
ADHD subtype, n (%)
Combined 2 (25.0) 1 (14.3) 36 (56.3) 28 (46.7) 10 (37.0) 48 (48.5) 29 (43.3)
Inattentive 6 (75.0) 6 (85.7) 27 (42.2) 30 (50.0) 16 (59.3) 49 (49.5) 36 (53.7)
Hyperactive/impulsive 0 (0) 0 (0) 1 (1.6) 2 (3.3) 1 (3.7) 2 (2.0) 2 (3.0)
Prior stimulant exposure, n (%) 5 (17.2) 7 (24.1) 27 (42.2) 16 (26.7) 10 (37.0) 42 (35.0) 23 (25.8)
Demographics and characteristics may not have been reported for all patients included in the analyses.
ADHD, attention-deficit/hyperactivity disorder; ATX, atomoxetine; N, overall number of patients in group; n, number of patients; PBO, placebo.
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Table 2. Changes in Reading Abilities—Baseline to Week 16
Measure Tx
Dyslexia ADHD+ dyslexia ADHD only
Baseline
LSM
changea
Effect
size Baseline
LSM
changea
Effect
size Baseline
LSM
change
Woodcock Johnson III ATX n = 19
PBO n = 22
ATX n = 51
PBO n = 55
ATX n= 22
Word Attack ATX 84.11 4.28*{ 0.718 84.82 2.38{ 0.137 101.91 -1.20
PBO 88.05 -3.20* 86.53 1.25
Word Identification ATX 80.47 4.11* 0.033 81.45 0.30 0.183 101.50 -0.56
PBO 83.86 0.89 87.55 -1.25
Basic Reading Skills ATX 80.26 5.40**{ 0.478 81.61 1.31 0.137 101.95 -0.85
PBO 84.77 -0.52 85.82 0.22
Reading Vocabulary ATX 86.42 4.19*{ 0.731 85.84 -0.11{ 0.074 96.05 -4.92*
PBO 90.91 -2.97 91.87 -1.10
Passage Comprehension ATX 83.74 -1.27 0.112 83.90 -2.88 0.010 97.14 -4.86*
PBO 85.95 0.21 88.45 -3.63*
Reading Comprehension ATX 82.58 2.13 0.270 82.22 -1.60 0.111 95.86 -5.77**
PBO 86.23 -1.33 88.45 -3.14*
Reading Fluency ATX 84.95 0.63 0.130 82.51 0.12 0.015 95.95 1.54
PBO 84.36 -0.62 89.09 0.02
Spelling ATX 77.32 -0.77 0.362 79.06 0.19 0.394 100.50 0.04
PBO 83.32 -3.50 84.15 -3.60*
Spelling of sounds ATX 84.95 -1.76 0.504 82.16 5.66** 0.161 88.23 9.58**
PBO 80.45 6.45* 80.69 3.86
Comprehensive Test of
Phonological Processing
ATX n = 20
PBO n = 22
ATX n = 51
PBO n = 55 ATX n= 22
Elision ATX 7.10 0.03 0.097 6.69 0.72{ 0.499 9.55 -0.01
PBO 7.59 -0.36 7.69 -0.46
Blending words ATX 8.65 2.00** 0.093 9.27 0.97** 0.008 9.45 2.07***
PBO 8.73 1.94*** 8.78 1.08***
Phonological awareness ATX 87.20 4.69 0.022 88.00 5.09** 0.343 96.59 6.31*
PBO 87.45 5.15 89.15 1.87
Memory for digits ATX 8.15 0.58 0.148 8.18 0.45{ 0.177 9.82 -0.62
PBO 7.73 0.00 7.96 0.08
Nonword repetition ATX 8.75 1.14* 0.108 8.29 0.59 0.032 9.09 1.02*
PBO 8.05 0.67 8.69 0.45
Phonological memory ATX 90.70 4.45 0.112 89.14 2.83 0.122 97.82 1.51
PBO 85.82 4.24 90.07 1.00
Rapid letterb naming ATX 7.85 -0.14 0.515 7.33 0.26 0.041 8.68 -0.02
PBO 7.73 -0.94* 7.84 0.21
Rapid digitb naming ATX 8.00 0.04 0.251 7.30 0.31 0.051 8.95 0.06
PBO 7.14 -0.15 7.69 0.14
Rapid namingb ATX 87.55 -4.04 0.151 84.14 1.62 0.070 92.18 -1.37
PBO 83.09 -2.18 86.89 0.46
Gray Oral Reading Tests-4
ATX n = 20
PBO n = 22
ATX n = 51
PBO n = 55 ATX n= 21
Accuracy ATX 5.35 1.39** 0.181 5.33 0.77* 0.146 8.10 0.71
PBO 5.50 0.73 6.31 0.43
Rate ATX 5.65 1.21* 0.204 5.67 0.14 0.090 9.00 0.04
PBO 5.50 0.72 6.98 -0.02
Fluency ATX 4.05 1.43** 0.006 4.33 0.78 0.164 7.67 0.63
PBO 4.18 1.18** 5.78 0.25
Comprehension ATX 7.80 0.30 0.197 8.14 0.24 0.117 9.62 -0.41
PBO 8.14 1.03 8.69 0.54
Oral reading quotient ATX 72.35 11.22* 0.184 76.41 -2.19 0.199 91.86 -1.04
PBO 77.50 3.55 82.07 2.25
TOWRE
ATX n = 22
PBO n = 28
ATX n = 61
PBO n = 57 ATX n= 26
Phonemic decoding ATX 81.45 0.81 0.052 80.98 2.48** 0.127 96.69 1.80
PBO 81.43 1.13 83.70 1.75*
Sight word ATX 86.09 0.75 0.025 83.89 1.41 0.035 94.88 0.52
PBO 84.50 0.08 87.25 1.19
Total TOWRE ATX 80.41 7.28 0.344 81.77 3.31 0.191 102.35 -4.53
PBO 79.54 0.64 82.61 8.11**
Bolded values denote change in atomoxetine group was statistically significantly greater than placebo, p < 0.02.
aLSM values were derived from a model comparing atomoxetine-treated patients with placebo-treated patients within the diagnostic group.
bADHD +D group only: Atomoxetine n = 49 for rapid naming and rapid letter naming and n = 50 for rapid digit naming.
Within-treatment group p-values: *p £ 0.05; **p < 0.01; ***p < 0.001. Within-group p-values are from t-tests on LSM change, ANCOVA model: Change= treatment
group+study site+gender+age (type III sums of squares).
{ATX versus placebo p < 0.02; ANCOVA model: Change = treatment group+study site+gender+age (type III sums of squares).
{p< 0.05 ADHD+D (atomoxetine) versus ADHD (atomoxetine) p-value. p-Values are from the ANCOVA model: Change= diagnostic group+study
site+gender+age (type III sums of squares).
ADHD, attention-deficit/hyperactivity disorder; ANCOVA, analysis of covariance; ATX, atomoxetine; LSM, least-squares mean; n, number of
patients; PBO, placebo; TOWRE, test of word reading efficiency; Tx, treatment.
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fatigue, upper abdominal pain, decreased appetite, somnolence, and
aggression. More detailed baseline demographics and characteristics
and safety outcomes were reported in a previous publication
(Wietecha et al. 2013).
Reading ability
The changes from baseline to 16 weeks and ES of treatment
in reading abilities for each diagnostic group are shown in Table 2.
Dyslexia-only patients in the atomoxetine group showed significantly
greater gains ( p< 0.02) in reading scores relative to the placebo
group, with moderate to high treatment ES on WJIII measures of
Word Attack (ES = 0.72), Basic Reading Skills (ES = 0.48), and
Reading Vocabulary (ES = 0.73). In addition, within-group chan-
ges from baseline to 16 weeks in dyslexia-only patients with ato-
moxetine treatment were significant ( p < 0.05) for several WJIII,
CTOPP, and GORT-4 measures (Fig. 2).
Patients with ADHD +D treated with atomoxetine showed
greater improvement on the CTOPP Elision measure compared
with placebo-treated patients ( p< 0.02), with a moderate treat-
ment ES (ES = 0.50). Comparisons of LSM changes in reading
abilities between atomoxetine-treated patients with dyslexia only
and ADHD +D revealed no significant differences. However,
atomoxetine-treated patients with ADHD +D had significantly
( p < 0.05) greater score increases on the WJIII Word Attack score
and the CTOPP Memory for Digits score compared with the
ADHD-only group. From baseline to 16 weeks, within-group LSM
changes in the ADHD +D atomoxetine treatment group were sig-
nificant for several WJIII, CTOPP, and TOWRE measures
( p < 0.05). Results for patients with ADHD only showed significant
within-group LSM changes from baseline to 16 weeks for limited
WJIII and CTOPP measures ( p< 0.05).
Correlation between improvement in reading scores
and improvement in attention measures
After 16 weeks of treatment, ADHD symptom improvements in
the ADHD +D group were not correlated with improvements in
reading (data not shown). Furthermore, improvements in reading
measures and ADHD symptoms were not significantly correlated
with demographic parameters, including age, gender, income sta-
tus, education, and ADHD subtype.
ADHD symptom efficacy results
ADHD symptom decreases from baseline on the primary effi-
cacy measure total and subtype core ADHD symptoms after 16
weeks of double-blind treatment were significantly greater for pa-
tients treated with atomoxetine who had ADHD +D compared with
placebo ( p£ 0.02) (Supplementary Table S3). Similarly, patients
with ADHD only demonstrated significant decrease in ADHD
symptoms from baseline to 16 weeks ( p£ 0.02). As would be ex-
pected, patients with dyslexia only had no significant LSM within-
group changes from baseline to 16 weeks or significant differences
between treatment groups. Greater detail of efficacy results are
published elsewhere (Wietecha et al. 2013).
Discussion
In this randomized, placebo-controlled trial, atomoxetine
treatment resulted in significant improvements on multiple mea-
sures of reading in children and adolescents with dyslexia only or
ADHD+D. These results are particularly interesting in the older
age group recruited here because reading interventions are con-
siderably more effective in the early grades of school (Torgesen
et al. 2001). In particular, for patients with dyslexia only,
FIG. 2. Forest plot of reading measures for dyslexia patients treated with atomoxetine versus placebo. LSMs are raw means after
adjustment for study site, gender, and age. Values analyzed by using a type III sums of squares, analysis of variance (ANOVA) model:
variable = treatment group+study site+gender+age. CI, confidence interval; LS, least squares.
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atomoxetine treatment over the 16-week period resulted in sig-
nificant improvement in Word Attack, Basic Reading, and
Reading Vocabulary on the WJIII, with moderate-to-large ES. In
patients with ADHD+D, atomoxetine treatment resulted in a
significant improvement in phonological processing as measured
by Elision on the CTOPP, with a moderate ES. Importantly, the
improvements measured by ES achieved after 16 weeks of ato-
moxetine treatment are greater or comparable to those observed
with traditional and more labor-intensive interventions (National
Reading Panel 2000).
In this study, in patients with ADHD+D, baseline-to-endpoint
within-group improvements were achieved on some WJIII subtests
and other reading measures and separated from placebo on the
CTOPP Elision score. The magnitude of change on reading mea-
sures was modest but is very relevant for proof of concept (e.g., that
dyslexia can be improved with a medication). Changes represent
approximately one-third of a standard deviation change. It remains
to be seen if this positive change, in turn, creates other positive
downstream effects in reading skills. Of course, additional research
is necessary to better understand whether the magnitude of change
is clinically significant. These improvements in reading measures
were not correlated to improvement in overall ADHD symptoms or
changes in the inattentive symptoms. These results suggest that
the improvement in reading may not have been simply due to a
reduction in ADHD symptomatology. Furthermore, the reading
performance improvements were consistent with results from
previous, smaller studies in atomoxetine-treated children with
ADHD +D (de Jong et al. 2009; Sumner et al. 2009; Shaywitz
et al. 2014). As in previous atomoxetine studies, the improve-
ments in ADHD symptoms, overall and for the inattentive and
hyperactive/impulsive subtypes, did not correlate with increases in
reading scores or academic achievement (Weiss et al. 2007; de Jong
et al. 2009; Sumner et al. 2009).
When considering improvement in phonological processing and
reading skills, one must also take into account the important role of
working memory (short-term memory in the context of other
concurrent mental operations) in all types of language processing.
In a prior article using the current data set (Wietecha et al. 2013),
we demonstrated improvement in some areas of working memory
in an ADHD +D sample following treatment with atomoxetine.
However, working memory improvement does not appear to be
related to reading improvement in the present data, based on non-
significant correlations between improvement in reading skills and
ADHD symptoms (including attention and mental effort, which are
highly related to working memory). However, because working
memory is an important component of executive and language
functioning and is impaired in patients with ADHD only and
ADHD+D, further research to elucidate the working memory-
reading outcome relationship in the context of medication treat-
ment is warranted.
We note several limitations of the current results. First, in the
study of dyslexia, an inherent design limitation is the selection of
any operational definition, as it may have an impact on results. It is
widely agreed that not every child with dyslexia demonstrates a
discrepancy between reading achievement skills or phonological
processing and IQ. The mechanism resulting in poor reading and
phonological skills may also contribute to lower IQ scores. In this
study, the operational definition of dyslexia was conservative by
allowing for both a discrepancy and a low achievement. Second,
many of the statistical analyses were performed without correc-
tion for baseline scores. The a priori-specified analysis for ad-
justment of baseline scores may not have been an appropriate
analysis for the primary ADHD efficacy measures as all patients
did not have ADHD. Therefore, this adjustment may have ob-
scured a difference by using an overall mean across diagnoses in
calculation of LS means, thereby inflating the scores in the
dyslexia-only group up to levels consistent with the ADHD +D
group. Third, the effects of the baseline adjustment may have been
over-influenced by ADHD +D patients, given the larger vari-
ability of baseline values for this group of patients. To account for
this potentially limiting factor, the data were examined with the
adjustment for baseline score excluded from the model in the post
hoc analysis. Similarly, the reading measures were also re-
analyzed excluding the baseline adjustment from the model, since
differences may have been obscured by using an overall mean
across diagnoses.
The data from this well-controlled study offer novel and com-
pelling evidence to suggest that atomoxetine treatment improved
reading outcomes in adolescents with dyslexia only and with co-
morbid ADHD and dyslexia over a 16-week treatment period. As
noted earlier, many reading researchers have become disappointed
with the results of traditional reading intervention programs that
‘‘.can best be described as producing limited successes’’
(Compton et al. 2014). At the same time, we emphasize that chil-
dren with dyslexia must be taught to read and that atomoxetine
treatment could serve as an effective pharmacologic adjunct to these
more traditional school-based reading interventions. The substan-
tial lifelong negative impact of dyslexia on many of the most crit-
ical factors influencing a person’s life—education, employment,
health—presents a powerful argument that potential additions to the
armamentarium to improve reading in those who have dyslexia—in
this case, pharmacotherapy—not be overlooked. These findings
provide proof of concept for this aim as well as potential relief for
the larger public health concerns related to dyslexia.
Conclusions
Atomoxetine treatment improved reading scores in patients with
dyslexia only and in a randomized, double-blind trial. Improve-
ments for patients with dyslexia only were in critical components of
reading, including decoding and reading vocabulary. For patients
with dyslexia and comorbid ADHD, improvements in reading
scores were distinct from improvement in ADHD inattention
symptoms alone.
Clinical Significance
This study adds important new information for the treatment of
dyslexia as follows: (1) uses a randomized, double-blind placebo
control design; (2) demonstrates that, in children with dyslexia,
atomoxetine exerts significant positive effects on reading and
phonological processing presumably by influencing prefrontal at-
tentional mechanisms which then influence phonological proces-
sing; and (3) suggests that this treatment may serve as a new and
useful adjunct to current therapy for dyslexia.
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